Advaxis Inc. (NASDAQ:ADXS) was up 4.8% on Monday . The company traded as high as $14.93 and last traded at $14.86, with a volume of 479,454 shares changing hands. The stock had previously closed at $14.18.

A number of equities research analysts have weighed in on ADXS shares. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Advaxis in a report on Friday, August 5th. Jefferies Group reaffirmed a “buy” rating on shares of Advaxis in a report on Friday, June 10th. FBR & Co reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Advaxis in a report on Thursday, July 7th. Finally, Barclays PLC lifted their price objective on Advaxis from $15.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, August 3rd. Six research analysts have rated the stock with a buy rating, Advaxis has an average rating of “Buy” and a consensus price target of $25.80.

The stock’s market cap is $508.66 million. The company has a 50 day moving average of $9.66 and a 200 day moving average of $8.41.

In related news, Director David Sidransky sold 22,808 shares of the stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $15.01, for a total transaction of $342,348.08. Following the sale, the director now owns 91,759 shares in the company, valued at $1,377,302.59. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Richard J. Berman sold 18,000 shares of the stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $15.21, for a total transaction of $273,780.00. Following the sale, the director now owns 66,430 shares in the company, valued at approximately $1,010,400.30. The disclosure for this sale can be found here.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.